Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
Funding Agency:
- National Institutes of Health
The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. The program supports the development of critical tools and resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities.
ITCR provides support for informatics technology development through four FOAs aimed at distinct phases of the technology development lifecycle:
- RFA-CA-22-021 (this FOA, R21, Clinical Trial Optional) Supports the development of highly innovative informatics methods and algorithms
- RFA-CA-22-022 (U01, Clinical Trial Optional) Supports initial tool development or the significant modification of existing tools for new applications
- RFA-CA-22-023 (U24, Clinical Trial Optional) Supports the continued development of emerging informatics technology that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement.
- RFA-CA-22-024 (U24, Clinical Trial Optional) Supports sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources.
Specific Research Objectives and Scope of this FOA
This FOA invites applications that involve the development of highly innovative methods and algorithms that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research. The emphasis will be on innovation and potential impact on cancer research. In addition, all projects proposed in response to this FOA must involve the following general attributes:
- Capabilities that are potentially transformative for a cancer-relevant field of research
- Potential to be widely-adopted by the relevant cancer research community
- Innovation either in the method/algorithm developed or in how the method/algorithm is modified and taken from one field and applied in another
The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
June 14, 2022; November 17, 2022
Juli Klemm, Ph.D., National Cancer Institute (NCI), Telephone: 202-853-7889, Email: juli.klemm@.nih.gov